Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Steven M. Archer, MD

Advertisement

Articles by Steven M. Archer, MD

Ophthalmoplegia surgical outcomes vary upon degree of eye paresis

BySteven M. Archer, MD,Fred Gebhart
June 14th 2018
Advertisement

Latest Updated Articles

  • Ophthalmoplegia surgical outcomes vary upon degree of eye paresis
    Ophthalmoplegia surgical outcomes vary upon degree of eye paresis

    Published: June 14th 2018 | Updated:



Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

Regeneron receives another CRL for its Eylea 8 mg

2

Topcon Healthcare seeks to advance company through acquisition and new investment

3

What if? Ophthalmology without OCT – Part 3

4

Eli Lilly to acquire Adverum Biotechnologies

5

Anti-VEGF innovations in retinal disease: From molecules to medicine

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us